Merck’s (NYSE:MRK) monoclonal antibody Zinplava (bezlotoxumab) for recurrent Clostridium difficile infection (RCDI) is likely to encounter significant reimbursement obstacles with a potentially high price, experts said. Because hospitals are the likely payers, Zinplava’s cost-benefit profile could be hard pushed in proving it deserves a large chunk of a small funding pie, they added.
To offset limitations of hospital funding, Zinplava could seek approval from different funding sources, experts said. Failing that, Merck could argue to hospitals Zinplava’s single-infusion administration is not a cost burden and use could be a long-term hospital budget solution, they added.
This news service reported on 19 July Zinplava has a positive approval chance due to encouraging Phase III efficacy/safety data but real world data is critical for uptake success.